Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak
Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Finite clinical data and understanding of COVID-19 immunopathology has led to limited, opinion-based recommendations for the management of patients with immune-mediated inflammatory disease (IMID) receiving immunosuppressive (IS) therapeutics.
OBJECTIVE: To determine if IS therapeutic type affects COVID-19 risk among patients with IMID.
METHODS: We conducted a retrospective cohort analysis of Henry Ford Health System patients tested for COVID-19 between February 1 and April 18, 2020, treated with IS medication for IMID. Therapeutic class of IS medication, comorbidities, and demographic factors were combined into multivariate models to determine predictors of COVID-19 infection, admission, ventilation, and mortality.
RESULTS: Of 213 patients with IMID, 36.2% tested positive for COVID-19, and they had no greater odds of being hospitalized or requiring ventilation relative to the general population. No IS therapeutic worsened the course of disease after multivariate correction, although multidrug regimens and biologics predicted an increased and decreased rate of hospitalization, respectively, with the latter driven by tumor necrosis factor α inhibitors.
LIMITATIONS: A single-center study somewhat limits the generalization to community-based settings. Only patients tested for COVID-19 were analyzed.
CONCLUSION: IS therapies for IMIDs are not associated with a significantly greater risk of SARS-CoV-2 or severe sequelae when controlling for other factors, and tumor necrosis factor α inhibitors may decrease the odds of severe infection.
| Errataetall: |
CommentIn: J Am Acad Dermatol. 2023 Jun;88(6):1385-1386. - PMID 36773822 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
Journal of the American Academy of Dermatology - 83(2020), 6 vom: 01. Dez., Seite 1696-1703 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Veenstra, Jesse [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.12.2020 Date Revised 15.06.2023 published: Print-Electronic CommentIn: J Am Acad Dermatol. 2023 Jun;88(6):1385-1386. - PMID 36773822 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaad.2020.07.089 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313114560 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313114560 | ||
| 003 | DE-627 | ||
| 005 | 20231225145854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaad.2020.07.089 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM313114560 | ||
| 035 | |a (NLM)32735965 | ||
| 035 | |a (PII)S0190-9622(20)32290-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Veenstra, Jesse |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.12.2020 | ||
| 500 | |a Date Revised 15.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Am Acad Dermatol. 2023 Jun;88(6):1385-1386. - PMID 36773822 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Finite clinical data and understanding of COVID-19 immunopathology has led to limited, opinion-based recommendations for the management of patients with immune-mediated inflammatory disease (IMID) receiving immunosuppressive (IS) therapeutics | ||
| 520 | |a OBJECTIVE: To determine if IS therapeutic type affects COVID-19 risk among patients with IMID | ||
| 520 | |a METHODS: We conducted a retrospective cohort analysis of Henry Ford Health System patients tested for COVID-19 between February 1 and April 18, 2020, treated with IS medication for IMID. Therapeutic class of IS medication, comorbidities, and demographic factors were combined into multivariate models to determine predictors of COVID-19 infection, admission, ventilation, and mortality | ||
| 520 | |a RESULTS: Of 213 patients with IMID, 36.2% tested positive for COVID-19, and they had no greater odds of being hospitalized or requiring ventilation relative to the general population. No IS therapeutic worsened the course of disease after multivariate correction, although multidrug regimens and biologics predicted an increased and decreased rate of hospitalization, respectively, with the latter driven by tumor necrosis factor α inhibitors | ||
| 520 | |a LIMITATIONS: A single-center study somewhat limits the generalization to community-based settings. Only patients tested for COVID-19 were analyzed | ||
| 520 | |a CONCLUSION: IS therapies for IMIDs are not associated with a significantly greater risk of SARS-CoV-2 or severe sequelae when controlling for other factors, and tumor necrosis factor α inhibitors may decrease the odds of severe infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a DMARDs | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a autoimmune disease | |
| 650 | 4 | |a biologics | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a immune-mediated inflammatory diseases | |
| 650 | 4 | |a immunosuppression | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a TNF protein, human |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 700 | 1 | |a Buechler, Connor R |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Gabrielle |e verfasserin |4 aut | |
| 700 | 1 | |a Chapman, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Adelman, Madeline |e verfasserin |4 aut | |
| 700 | 1 | |a Tisack, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Dimitrion, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Todter, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Kohen, Laurie |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Henry W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Academy of Dermatology |d 1984 |g 83(2020), 6 vom: 01. Dez., Seite 1696-1703 |w (DE-627)NLM000422703 |x 1097-6787 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2020 |g number:6 |g day:01 |g month:12 |g pages:1696-1703 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaad.2020.07.089 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2020 |e 6 |b 01 |c 12 |h 1696-1703 | ||